# Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD

> **NCT02684578** · PHASE2 · COMPLETED · sponsor: **University of California, San Francisco** · enrollment: 66 (actual)

## Conditions studied

- Age-Related Macular Degeneration
- Macular Degeneration, Age-Related
- Dry Macular Degeneration
- Geographic Atrophy

## Interventions

- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT02684578
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2022-04
- **Final completion:** 2022-10
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2023-06-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02684578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02684578, "Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD". Retrieved via AI Analytics 2026-09-12 from https://api.ai-analytics.org/clinical/NCT02684578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*